Google Übersetzer
Sab Biotherapeutics Inc
About
Sab Biotherapeutics Inc (NASDAQ:SABS) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 22 2026
SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026
Apr 15 2026
SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress
Mar 19 2026
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
Mar 17 2026
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
Mar 17 2026
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Recent Videos
SAB Biotherapeutics: Revolutionizing Diabetes Treatment! ##DiabetesTreatment #InsulinProduction
Apr 06, 2026
Cómo invertir en SAB Biotherapeutics Inc (SABS) paso a paso
Mar 22, 2026
FTR Biotech Analysis: SAB Biotherapeutics
Mar 15, 2026
SAB Biotherapeutics Stock Analysis: 100% Human Antibodies, No Donors Needed
Feb 06, 2026